Skip to main content

Table 4 Change in neurodevelopment test score according to time of mPBMC infusion

From: Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study

 

M0–M13

M1–M13

T1

T7

p

T1

T7

p

GMFM

4.28

8.30

0.002

2.90

6.37

0.001

 Lying

1.34

1.33

0.398

0.89

0.71

0.780

 Sitting

2.65

9.08

0.103

1.74

7.35

0.044

 Crawling

5.19

12.86

0.010

2.92

10.41

0.002

 Standing

4.78

7.18

0.093

3.50

5.13

0.079

 Walking

7.45

10.02

0.391

5.43

8.45

0.198

PEDI_selfcare

8.64

8.13

0.370

5.58

6.54

0.204

 Mobility

8.86

10.00

0.856

6.35

6.53

0.621

 Social function

13.78

9.33

0.327

9.54

6.28

0.296

 Selfcare (caregiver)

7.88

10.92

0.228

5.54

8.44

0.455

 Mobility (caregiver)

4.90

7.28

0.221

3.29

6.22

0.052

 Social function (caregiver)

11.45

14.65

0.236

8.87

12.13

0.208

QUEST

21.28

25.66

0.394

13.79

18.44

0.183

  1. mPBMC mobilized peripheral blood mononuclear cell; GMFM gross motor function measure; PEDI pediatric evaluation of disability inventory; QUEST quality of upper extremity skills test. M0, M1, and M13 refer to months after enrollment. T1 and T7 refer to a group who received mPBMC at 1 and 7 months of study, respectively
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us